丰原药业(000153) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥876,165,996.14, representing a 3.26% increase compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥26,630,100.86, a significant increase of 106.52% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,620,720.44, up 256.70% from the previous year[3] - Basic earnings per share for Q3 2021 was ¥0.0853, an increase of 106.54% year-on-year[3] - The total operating revenue for the third quarter of 2021 was CNY 2,619,574,442.63, an increase of 7.98% compared to CNY 2,426,272,151.86 in the same period last year[17] - The net profit for the third quarter was CNY 88,341,496.74, representing a 25.3% increase from CNY 70,492,698.84 in the previous year[19] - The earnings per share (EPS) for the period was CNY 0.2890, compared to CNY 0.2263 in the same quarter last year, indicating a growth of 27.8%[19] - The total comprehensive income for the quarter was CNY 88,520,393.89, compared to CNY 59,471,810.67 in the same period last year, indicating a significant increase[19] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥3,767,473,524.33, a 3.61% increase from the end of the previous year[3] - Total current assets as of September 30, 2021, amount to ¥1,705,883,434.34, a decrease from ¥1,738,288,251.02 at the end of 2020[15] - Total assets as of September 30, 2021, are ¥3,767,473,524.33, up from ¥3,636,207,572.40 at the end of 2020[15] - The total liabilities as of the end of the third quarter were CNY 2,232,586,373.98, slightly up from CNY 2,188,230,845.23[17] - Total liabilities amounted to ¥1,800,000,000.00, indicating a stable financial position despite fluctuations in cash flow[26] - Total liabilities amounted to CNY 2,188,230,845.23, with current liabilities at CNY 2,065,177,727.62[27] - Non-current liabilities totaled CNY 123,053,117.61, including long-term borrowings of CNY 27,037,500.00[27] Shareholder Information - Shareholders' equity attributable to the parent company was ¥1,503,707,010.25, up 6.38% from the previous year[3] - Total number of common shareholders at the end of the reporting period is 29,549[11] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[12] - The total equity attributable to shareholders of the parent company increased to CNY 1,503,707,010.25 from CNY 1,413,489,476.40, marking a growth of 6.4%[17] - Total equity reached CNY 1,447,976,727.17, with attributable equity to shareholders at CNY 1,413,489,476.40[27] Cash Flow - The operating cash flow net amount for the year-to-date was ¥120,300,008.93, reflecting a 167.02% increase compared to the same period last year[3] - The company reported a total cash flow from operating activities of CNY 123,389,224.71 for the quarter, up from CNY 98,300,540.59 year-over-year[19] - Total cash inflow from operating activities reached ¥3,109,896,047.15, compared to ¥2,829,637,923.69 in the prior period, indicating a growth of approximately 9.9%[22] - Cash outflow for purchasing goods and services was ¥2,122,986,880.24, an increase from ¥1,809,836,655.29, reflecting a rise of about 17.3%[22] - The net cash flow from investing activities was -¥109,571,881.37, slightly improved from -¥111,972,916.56 in the previous period[23] - Cash inflow from financing activities totaled ¥763,766,257.12, down from ¥908,405,007.38, showing a decrease of approximately 15.9%[23] - Cash outflow for debt repayment was ¥729,500,000.00, compared to ¥843,677,121.00 previously, indicating a reduction of about 13.5%[23] - The ending balance of cash and cash equivalents was ¥240,432,924.87, an increase from ¥220,688,650.37, marking a growth of approximately 8.5%[23] Research and Development - The company reported a significant increase in R&D expenses, totaling ¥73,446,859.39, which is a 40.49% increase year-on-year[8] - Research and development expenses for the quarter were CNY 50,606,084.29, compared to CNY 48,898,789.79 in the previous year, reflecting an increase of 2.4%[19] - The company has ongoing development expenditures of ¥73,446,859.39, up from ¥52,278,192.01[15] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Other Financial Information - The company received government subsidies amounting to ¥12,176,376.66 during the reporting period, contributing to its non-recurring gains[5] - The company experienced a 222.19% increase in long-term borrowings, reaching ¥87,111,283.33, indicating a strategic shift in financing[9] - The company implemented new leasing standards affecting the financial statements, which may impact future reporting and financial metrics[24] - The report for the third quarter of 2021 was not audited[28] - The company has implemented new leasing standards starting from 2021, with no retrospective adjustments made to prior comparative data[28] - The total amount of other payables was CNY 542,281,489.43[27] - The company has a deferred income of CNY 77,262,652.87[27] - The total amount of undistributed profits was CNY 518,891,038.45[27] - The company’s total current liabilities include a significant portion of short-term debts[27]